Dr. Thomas M. Siler, MD
Pulmonology (Pulmonary Disease Physician)
300 1st Capitol Dr
Saint Charles, MO 63301
Who else practices at this address →
St. Charles County is a federal mental health shortage area; it also includes dental (16% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 504
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MO license R6D67 -
Critical Care Medicine (Internal Medicine) Physician
MO license R6D67 -
Sleep Medicine (Internal Medicine) Physician
MO license R6D67
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ssm St Joseph Health Center Saint Charles, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
- Ssm St Joseph Hospital West Lake Saint Louis, MO
Medical groups
- Ssm Health Care St Louis (167 clinicians)
- Midwest Chest Consultants PC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 504
- Services billed
- 2,160
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 863 | 434 |
| Test to measure rate of airflow | 494 | 194 |
| Test to measure the level of nitric oxide gas | 154 | 60 |
| Established patient office or other outpatient visit, 40-54 minutes | 116 | 56 |
| Administration of influenza virus vaccine | 80 | 80 |
| Influenza vaccine split virus, preservative free | 79 | 79 |
| Test to examine how well the lungs exchange gases | 61 | 61 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 60 | 60 |
| Test to determine lung volumes using sensors | 58 | 58 |
| Evaluation of use of breathing device | 55 | 50 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Saint Charles, MO | 118 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Saint Charles, MO | 98 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Saint Charles, MO | 90 |
| Prednisone Other prescribers in Saint Charles, MO | 71 |
| Zolpidem Tartrate Other prescribers in Saint Charles, MO | 70 |
| Clonazepam Other prescribers in Saint Charles, MO | 46 |
| Modafinil Other prescribers in Saint Charles, MO | 41 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Saint Charles, MO | 37 |
| Shingrix (varicella-zoster ge/as01b/pf) Other prescribers in Saint Charles, MO | 35 |
| Dextroamphetamine Sulfate | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 99 payments worth $3,265 in total to this clinician.
| Genzyme Corporation | $699 |
|---|---|
| Verona Pharma, Inc. | $475 |
| GlaxoSmithKline, LLC. | $307 |
| Regeneron Healthcare Solutions, Inc. | $284 |
| Jazz Pharmaceuticals Inc. | $272 |
| Avadel Cns Pharmaceuticals, LLC | $238 |
| AstraZeneca Pharmaceuticals LP | $174 |
| Harmony Biosciences LLC | $172 |
| Food and Beverage | $2,851 |
|---|---|
| Consulting Fee | $411 |
| Education | $2.82 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Avadel Cns Pharmaceuticals, LLC Apr 15, 2025 | Consulting Fee LUMRYZ · CENTRAL NERVOUS SYSTEM CNS NEUROLOGY · in-kind | $200 |
| Jazz Pharmaceuticals Inc. Jan 28, 2025 | Consulting Fee XYWAV; XYREM · NEUROLOGY | $150 |
| Adma Biomanufacturing LLC Aug 22, 2025 | Consulting Fee | $38.75 |
| Adma Biomanufacturing LLC Nov 4, 2025 | Consulting Fee | $22.30 |
| Regeneron Healthcare Solutions, Inc. Apr 21, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $2.82 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 8 companies. The companies reported $1,127,174 in research payments for these studies, mostly to the institutions running them.
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Ob…
Verona Pharma, Inc. - A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Verona Pharma, Inc. - Ph III OLE of Astegolimab in COPD
Genentech, Inc. - A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc. - A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label…
AstraZeneca Pharmaceuticals LP - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared…
AstraZeneca Pharmaceuticals LP - A phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma
AstraZeneca UK Limited - Effect of Ensifentrine Treatment on CAT Score
Verona Pharma, Inc. - A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.